Acute Kidney Injury Treatment Market, by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, and Postrenal Acute Kidney Injury), by Treatment (Therapy, and Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and O

Acute Kidney Injury Treatment Market, by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, and Postrenal Acute Kidney Injury), by Treatment (Therapy, and Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Acute kidney injury (AKI) is characterized by a sudden loss in kidney function, characterized increasing serum creatinine level without loss of urine. Acute kidney injury affects other organs of the human body such as heart, lungs, and brain. Acute kidney injury is most common in patients admitted at hospital, intensive care units (ICU), and among older adults. Signs and symptoms of acute kidney failure may include decreased urine output, although occasionally urine output remains normal, fluid retention, causing swelling in legs, ankles or feet, shortness of breath, fatigue, confusion, nausea, weakness, irregular heartbeat, chest pain or pressure, and seizures or coma in severe cases.
Market Dynamics
Key players operating in the global acute kidney injury treatment market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of acute kidney injury, which is expected to drive the market growth during the forecast period. For instance, in October 2019, Astellas Pharma Inc. is a Japanese multinational pharmaceutical company., announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery. The fast track designation is intended to facilitate the development, and expedite the US FDA review, of drugs to treat serious and life-threatening conditions so that, if approved, the compounds can reach the market more expeditiously. Furthermore, in April 2021, Angion Biomedica Corp a late-stage biopharmaceutical company and Vifor Pharma a global pharmaceutical company announced completion of enrollment for Angion’s AKI-002-15 study, a Phase II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2021.
Key features of the study:
This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute kidney injury treatment market based on the following parameters – company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market
Detailed Segmentation:
Global Acute Kidney Injury Treatment Market, By Type :
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
Global Acute Kidney Injury Treatment Market, By Treatment :
Therapy
Drugs
Global Acute Kidney Injury Treatment Market, By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Acute Kidney Injury Treatment Market, By Region:
North America
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
itis
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
By Treatment
Therapy
Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Quark Pharmaceuticals, Inc.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Baxter International, Inc.
Novartis AG
B. Braun Melsungen AG
Fresenius Medical Care
Medtronic
Astellas Pharma Inc.
Sentien Biotechnologies, Inc.
Teva Pharmaceutical Industries Ltd.
Asahi Kasei Medical Co.
AM-Pharma B.V.
Teleflex Incorporated
Cure Medical, LLC
Angion Biomedia Corp
“*” marked represents similar segmentation in other categories in the respective section.